C R Dunstan
Overview
Explore the profile of C R Dunstan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
8133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Croucher P, Shipman C, Lippitt J, Perry M, Asosingh K, Hijzen A, et al.
Blood
. 2001 Dec;
98(13):3534-40.
PMID: 11739154
Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma...
12.
Brown J, Vessella R, Kostenuik P, Dunstan C, Lange P, Corey E
Clin Cancer Res
. 2001 Oct;
7(10):2977-83.
PMID: 11595685
Purpose: Osteoprotegerin (OPG) is a soluble osteoclastogenesis inhibitor that regulates bone turnover. We reported recently that OPG protein expression is significantly increased in prostate cancer (CaP) cells present in bone...
13.
Kostenuik P, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, et al.
Endocrinology
. 2001 Sep;
142(10):4295-304.
PMID: 11564687
PTH is a potent bone anabolic factor, and its combination with antiresorptive agents has been proposed as a therapy for osteoporosis. We tested the effects of PTH, alone and in...
14.
Bateman T, Dunstan C, Lacey D, Ferguson V, Ayers R, Simske S
J Orthop Res
. 2001 Aug;
19(4):518-23.
PMID: 11518255
This study examines the ability of osteoprotegerin (OPG) to prevent the local bone resorption caused by sciatic nerve damage. Sixty-five 18-week-old male mice were assigned to one of six groups...
15.
Morony S, Capparelli C, Sarosi I, Lacey D, Dunstan C, Kostenuik P
Cancer Res
. 2001 Jun;
61(11):4432-6.
PMID: 11389072
Certain malignancies, including breast cancer, frequently metastasize to bone, where the tumor cells induce osteoclasts to locally destroy bone. Osteoprotegerin (OPG), a member of the tumor necrosis factor receptor family,...
16.
Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, et al.
Mol Ther
. 2001 Mar;
3(2):197-205.
PMID: 11237676
Osteoprotegerin (OPG) regulates bone resorption by inhibiting osteoclast formation, function, and survival. The current studies employed a mouse ovariectomy (OVX) model of estrogen deficiency to investigate gene therapy with OPG...
17.
Bekker P, Holloway D, Nakanishi A, Arrighi M, Leese P, Dunstan C
J Bone Miner Res
. 2001 Feb;
16(2):348-60.
PMID: 11204435
Osteoprotegerin (OPG), a tumor necrosis factor (TNF) receptor family member, is a critical regulator of bone resorption. It is an important inhibitor of the terminal differentiation and activation of osteoclasts....
18.
Hofbauer L, Shui C, Riggs B, Dunstan C, Spelsberg T, OBrien T, et al.
Biochem Biophys Res Commun
. 2001 Feb;
280(1):334-9.
PMID: 11162519
Osteoporosis and vasculopathy are common after organ transplantation and have been largely attributed to the use of immunosuppressants. Osteoprotegerin (OPG) is produced by osteoblastic and arterial cells, and inhibits osteoclast...
19.
Gori F, Hofbauer L, Dunstan C, Spelsberg T, Khosla S, Riggs B
Endocrinology
. 2000 Dec;
141(12):4768-76.
PMID: 11108292
The one or more molecular mechanisms that determine the obligatory sequence of resorption followed by formation during bone remodeling is unclear. RANK ligand (RANK-L) is an essential requirement for osteoclastogenesis,...
20.
Min H, Morony S, Sarosi I, Dunstan C, Capparelli C, Scully S, et al.
J Exp Med
. 2000 Aug;
192(4):463-74.
PMID: 10952716
High systemic levels of osteoprotegerin (OPG) in OPG transgenic mice cause osteopetrosis with normal tooth eruption and bone elongation and inhibit the development and activity of endosteal, but not periosteal,...